L-DOPS
SIGMA/D9446 - ≥98% (HPLC)
Synonym: Droxidopa; L-threo 3,4-
CAS Number: 23651-95-8
Empirical Formula (Hill Notation): C9H11NO5
Molecular Weight: 213.19
MDL Number: MFCD00799030
Linear Formula: C9H11NO5
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to tan |
| form | powder |
| InChI | 1S/C9H11NO5/c10-7(9(14)15 |
| InChI key | QXWYKJLNLSIPIN-JGVFFNPUSA |
| Quality Level | 100  |
| SMILES string | N[C@@H]([C@H](O)c1ccc(O)c |
| solubility | DMSO: ≥3 mg/mL |
| storage condition | desiccated |
| storage temp. | −20°C |
| Application: | L-DOPS has been administered for clinical trial studies in mice with amyloid pathology. |
| Biochem/physiol Actions: | L-DOPS is a norepinephrine precursor in vivo. |
| Features and Benefits: | This compound is featured on the Dopamine, Norepinephrine and Epinephrine Synthesis page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| General description: | L-DOPS, also called L-threo 3,4-Dihydroxyphenylserine or droxidopa is a catecholamine. L-DOPS has many clinical advantages and may be useful for treating norepinephrine deficiency. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. L-DOPS mediates reduction of amyloid plaques and could have a therapeutic potential for treating amyloid pathology. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |